ReviewFrontiers in immunology2026
Neuronal surface autoantibodies at cerebellar and brainstem synapses: mechanisms, phenotypes, and translational gaps.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic neuronal-surface autoantibodies can disrupt extracellular receptors, ion-channel complexes, and synaptic proteins, yet their regional neurological phenotypes differ substantially. This variability is particularly informative in the cerebellum and brainstem, where precisely timed excitatory and inhibitory signaling supports motor coordination, ocular-motor control, autonomic regulation, arousal, and respiration. In this Mini Review, we examine how antibody effector mechanisms, regional antigen distribution, and local synaptic physiology interact to shape cerebellar and brainstem manifestations of neuronal-surface-antibody disease. Autoimmunity against metabotropic glutamate receptor 1 (mGluR1) provides a model of cerebellar synaptic dysfunction because mGluR1 is strongly linked to Purkinje-cell signaling and synaptic plasticity, whereas glycine receptor (GlyR) autoimmunity illustrates how impaired inhibitory transmission can destabilize brainstem and spinal networks. NMDAR, AMPAR, GABA_A receptor, GABA_B receptor, LGI1, and CASPR2 autoimmunity provide mechanistic comparators showing that extracellular antigen accessibility alone does not determine neurological phenotype. Direct antibody-mediated synaptic dysfunction may be reversible, but persistent structural injury occurs in a subset of patients; current evidence does not determine whether such injury is attributable to sustained antibody exposure, accompanying T-cell inflammation, or both. Evidence from acute physiological experiments, individual follow-up cases, and heterogeneous cohorts comes from different settings and does not establish a uniform progression from synaptic dysfunction to atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.